Company Encyclopedia
View More
name
SINOPHARM(CNCM LTD)
600511.SH
China National Medicines Corporation Ltd., together with its subsidiaries, engages in pharmaceutical equipment circulation in China. The company also manufactures and sells new drugs; sells Chinese patent medicines drug sales and western medicines, and medical equipment; and offers dental academic services, warehousing, logistics and import and export agency services. It also serves hospitals, retail pharmacies, and medical institutions. The company was founded in 1999 and is based in Beijing, China.
396.76 B
600511.SHMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
B
Health Care DistributorsIndustry
Industry Ranking4/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE11.61%B
    • Profit Margin3.87%C
    • Gross Margin6.79%E
  • Growth ScoreC
    • Revenue YoY1.48%C
    • Net Profit YoY-7.11%C
    • Total Assets YoY2.30%C
    • Net Assets YoY7.99%B
  • Cash ScoreB
    • Cash Flow Margin2583.15%A
    • OCF YoY1.48%C
  • Operating ScoreA
    • Turnover1.5A
  • Debt ScoreC
    • Gearing Ratio43.26%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SINOPHARM's subsidiary SINOPHARM(CNCM LTD) earned 1.492 billion RMB in the first three quarters, a slight increase of 0.7%

    SINOPHARM announced that its subsidiary SINOPHARM(CNCM LTD) reported operating revenue of RMB 3.9381 billion for the first three quarters, an increase of 3.6% year-on-year. The net profit attributable to shareholders was RMB 1.492 billion, a slight increase of 0.7%, with earnings per share of RMB 1.9778

    AASTOCKS·
    HK
    01099
    +1.09%
    SH
    600511
    +0.03%
    AASTOCKS·
    HK
    01099
    +1.09%
    SH
    600511
    +0.03%

    SINOPHARM (CNCM LTD) released its performance for the first three quarters, with a net profit attributable to the parent company of 1.492 billion yuan, a year-on-year increase of 0.74%

    According to the Zhitong Finance APP, SINOPHARM (CNCM LTD) disclosed its third-quarter report for 2025. In the first three quarters, the company achieved revenue of 39.381 billion yuan, a year-on-year increase of 3.56%; the net profit attributable to shareholders of the listed company was 1.492 billion yuan, a year-on-year increase of 0.74%; the net profit excluding non-recurring items was 1.47 billion yuan, a year-on-year decrease of 1.27%; the basic earnings per share were 1.9778 yuan

    Zhitong·
    SH
    600511
    +0.03%
    Zhitong·
    SH
    600511
    +0.03%

    Sinopharm Holdings: Sinopharm (CNCM LTD) reported a net profit attributable to shareholders of 949 million yuan in the first half of the year, a year-on-year decrease of 5.19%

    According to the Zhitong Finance APP, Sinopharm Holdings announced the performance of its subsidiary, SINOPHARM(CNCM LTD), for the first half of 2025, with operating revenue of approximately 25.634 billion yuan, a year-on-year increase of 3.54%. The net profit attributable to shareholders of the listed company was approximately 949 million yuan, a year-on-year decrease of 5.19%. The basic earnings per share were 1.2572 yuan

    Zhitong·
    SH
    600511
    +0.03%
    Zhitong·
    SH
    600511
    +0.03%

    Sinopharm Holdings' subsidiary, SINOPHARM (CNCM LTD), reported a slight decrease in net profit to 459 million RMB in the first quarter

    Sinopharm Holdings announced that its subsidiary, SINOPHARM(CNCM LTD), reported a revenue of RMB 12.713 billion in the first quarter, an increase of 4.9% year-on-year. The net profit attributable to shareholders was RMB 459 million, a slight decline of 0.1%, with earnings per share of 60.84 cents

    AASTOCKS·
    SH
    600511
    +0.03%
    AASTOCKS·
    SH
    600511
    +0.03%

    SINOPHARM released its first-quarter performance, with a net profit attributable to the parent company of 459 million yuan, a year-on-year decrease of 0.1%

    According to the Zhitong Finance APP, SINOPHARM (CNCM LTD) released its first quarter report for 2025. The company's first quarter operating revenue was 12.713 billion yuan, a year-on-year increase of 4.87%; the net profit attributable to shareholders of the listed company was 459 million yuan, a year-on-year decrease of 0.10%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 446 million yuan, a year-on-year decrease of 2.57%; the basic earnings per share was 0.6084 yuan/share

    Zhitong·
    SH
    600511
    +0.03%
    Zhitong·
    SH
    600511
    +0.03%
    © 2025 Longbridge｜Disclaimer